Highlights

  • Actinogen Medical received a third independent Data Monitoring Committee recommendation to continue its XanaMIA Alzheimer's trial without changes.
  • The review covered safety data from all 247 enrolled patients in the Phase 2b/3 study.
  • XanaMIA remains blinded, with topline cognitive and functional results expected in November 2026.
  • Actinogen completed a $16.8 million Capital raise in February 2026 to support operations through the planned readout period.

Actinogen Medical (ASX:ACW) has cleared another milestone on the pathway toward one of the company's most important clinical data events. The company confirmed on 18 June 2026 that an independent Data Monitoring Committee (DMC) had recommended its pivotal XanaMIA trial continue without changes after reviewing safety data from all 247 enrolled Alzheimer's disease patients.

The update represents a procedural milestone rather than a clinical outcome, as the trial remains blinded and there is no indication yet whether Xanamem can demonstrate efficacy. However, for Actinogen (ASX:ACW), which is approaching its planned November 2026 topline readout, the latest review removes another potential source of trial disruption before final results are released.

What Was Announced?

The 18 June announcement detailed the outcome of the third DMC safety review of the XanaMIA Phase 2b/3 trial, Actinogen's pivotal study evaluating its lead drug Xanamem (emestedastat) in mild-to-moderate Alzheimer's disease.

A DMC is an independent panel of clinicians and statisticians that reviews trial safety data separately from the company and investors. The committee can recommend that a study continue, be modified or be stopped depending on its findings. In this case, the DMC reviewed safety data from the complete 247-patient cohort and recommended the study proceed as designed.

More than 100 participants had completed the trial's 36-week treatment period at the time of the review. The company stated that this was the third independent safety review during the trial, following an earlier interim analysis announced in February 2026 that also recommended continuation without changes.

The XanaMIA trial is evaluating daily Xanamem 10mg against placebo, with the primary focus on cognitive and functional outcomes in patients with mild-to-moderate Alzheimer's disease.

Why This Matters

For a clinical-stage biotechnology company such as Actinogen (ASX:ACW), safety-related issues can create delays, trial modifications or interruptions before efficacy data becomes available. Three consecutive DMC recommendations indicate that no safety-related issue has required changes to the trial design to date.

However, the review does not provide information on whether Xanamem is effective. The drug's mechanism involves inhibiting the enzyme 11β-HSD1 to reduce excess cortisol activity in the brain without affecting adrenal gland function, but its ability to slow cognitive decline remains unproven in a pivotal-sized study.

The key upcoming milestone remains the November 2026 topline readout, which is expected to provide data on the trial's primary cognitive and functional endpoints.

Company Background

Actinogen Medical (ASX:ACW) is an ASX-listed clinical-stage pharmaceutical company focused on Xanamem, an oral brain-penetrant 11β-HSD1 inhibitor designed to target cortisol dysregulation associated with neurodegenerative and psychiatric conditions.

The company has reported that Xanamem has been evaluated across eight Clinical Trials involving more than 500 volunteers. Its primary development program, XanaMIA, is a randomised, placebo-controlled Phase 2b/3 study assessing Xanamem 10mg daily against placebo in mild-to-moderate Alzheimer's disease patients.

The full 247-patient cohort was enrolled in December 2025, and an open-label extension phase has commenced for eligible participants continuing on active treatment. XanaMIA remains the company's main development focus.

Financial Position

Actinogen completed a $16.8 million capital raise in February 2026, which increased its pro-forma cash position to approximately $29.5 million at that time.

The company has stated that this funding, together with non-dilutive sources such as Research and Development tax incentive receipts, extends its operational runway beyond the planned November 2026 XanaMIA readout.

The company's financial position remains focused on supporting the completion of the trial and preparation for the upcoming clinical milestone.

What Comes Next?

The next major event for Actinogen (ASX:ACW) is the planned XanaMIA topline data readout in November 2026. Final patient evaluations were expected to conclude in September 2026, supporting the release of results covering cognitive and functional endpoints over the 36-week treatment period.

If the trial demonstrates a clinical benefit, potential future steps could include regulatory discussions, additional clinical development and Partnership discussions. If results are inconclusive, the company may need to reassess the future direction of the Xanamem program.

Further scheduled updates are expected to include routine safety reviews and corporate announcements ahead of the topline results.

Risks

The primary risk for Actinogen (ASX:ACW) remains the binary outcome of the XanaMIA trial. Alzheimer's disease has historically presented significant challenges in late-stage drug development, and a clean safety profile does not confirm efficacy. Other risks include variability in cognitive trial endpoints, placebo effects, funding requirements if results are unclear, and broader capital market conditions that may influence future financing options.

Investor Takeaway

Actinogen's third independent DMC safety review confirms that the XanaMIA trial has progressed without safety-related changes through the full enrolled population, but it does not indicate whether Xanamem can demonstrate clinical benefit.

With enrolment completed, funding extended beyond the planned readout period, and three safety reviews completed, Actinogen (ASX:ACW) has reduced some operational uncertainties ahead of November 2026. The key unresolved Factor remains whether Xanamem can deliver meaningful cognitive and functional outcomes in Alzheimer's disease patients.